Treatment-resistant depression (TRD) affects an estimated 30% of the roughly 280 million people worldwide living with depression — those who have failed at least two adequate antidepressant trials. Ibogaine, a psychoactive alkaloid derived from the Tabernanthe iboga shrub, is attracting serious scientific attention as a potential rapid-acting intervention for TRD, particularly for people who have exhausted conventional options.

⚠️ Ibogaine carries serious cardiac risks and has caused fatalities. Medical supervision required. Do not self-administer.

What the Research Shows

Direct, placebo-controlled clinical trials of ibogaine specifically for treatment-resistant depression remain in early stages. However, a convergence of observational data, mechanistic research, and adjacent psychedelic trial results has driven growing scientific interest.

The most frequently cited clinical data touching on depression comes from the landmark Cherian et al. (2024) study published in Nature Medicine. This prospective, within-group study enrolled 30 special operations veterans — a population with extraordinarily high rates of comorbid PTSD and depression — and administered ibogaine with magnesium malate pre-treatment (used for its cardioprotective properties) at a clinic in Mexico. While the study's primary endpoints were PTSD symptom severity (measured by PCL-5) and functional disability (WHODAS), secondary measures captured significant reductions in depression and anxiety symptoms at the one-month follow-up. PTSD severity fell by 88% and disability scores fell by 87%. Because the study was specifically designed around PTSD and traumatic brain injury, these depression-related signals are hypothesis-generating rather than confirmatory for TRD as a standalone condition.

Beyond this, the evidence base for ibogaine and depression draws on several converging lines:

  • Case reports and observational data from ibogaine clinics in Mexico, the Netherlands, and Canada describe patients reporting lasting relief from depressive episodes following a single treatment session, sometimes after years of failed pharmacotherapy.
  • Noller et al. (2018), a prospective observational pilot published in the Journal of Psychoactive Drugs (N=14, mixed substance dependence), noted improvements in psychological wellbeing and mood beyond the primary addiction endpoints — consistent with ibogaine's broader anti-depressive signalling.
  • Preclinical evidence in rodent models demonstrates ibogaine's ability to upregulate GDNF (glial cell line-derived neurotrophic factor) and BDNF (brain-derived neurotrophic factor), both of which are implicated in the neurobiology of depression and are targets of next-generation antidepressant development.
  • The broader psychedelic medicine literature — particularly psilocybin trials for TRD by Carhart-Harris et al. and the COMPASS Pathways Phase IIb trial — establishes proof of concept that serotonergic and neuroplasticity-promoting compounds can produce rapid, durable antidepressant effects, lending biological plausibility to ibogaine research in TRD.

Dedicated Phase I/II trials examining ibogaine specifically for depression are currently in active development. Independent ibogaine research groups and academic centres in Canada, Brazil, and the US are designing protocols specifically targeting TRD populations.

Clinical Trial Results

No completed randomised controlled trial has yet tested ibogaine as a standalone intervention for treatment-resistant depression. The table below summarises the most relevant human evidence currently available.

Trial / Study Design N Key Depression-Relevant Outcome Year
Cherian et al. — Stanford/VETS Program Prospective observational (within-group), special operations veterans, PTSD/TBI focus 30 PTSD severity −88%, disability −87% at 1 month; secondary depression/anxiety improvements reported 2024
Noller et al. — New Zealand pilot Prospective observational, mixed substance dependence 14 Improved psychological wellbeing and mood measures alongside primary addiction endpoints 2018
Preclinical rodent models (multiple groups) Animal studies — BDNF/GDNF upregulation, forced swim test, learned helplessness paradigms N/A Antidepressant-like behavioural effects; neurotrophin upregulation Ongoing

No completed RCT exists for ibogaine in TRD specifically. Results above are from observational studies and preclinical work. Interpret with caution.

How Ibogaine May Help Treatment-Resistant Depression

Ibogaine's potential antidepressant mechanisms are multi-modal — which is precisely why researchers believe it may succeed where single-target antidepressants have failed in TRD populations.

Neuroplasticity and Neurotrophic Signalling

One of the most compelling hypotheses involves ibogaine's ability to rapidly upregulate BDNF (brain-derived neurotrophic factor) and GDNF (glial cell line-derived neurotrophic factor). Both play critical roles in synaptic plasticity, neuronal survival, and the remodelling of neural circuits implicated in mood regulation. The BDNF hypothesis of depression — which holds that reduced BDNF in the hippocampus and prefrontal cortex underlies depressive states — is well established, and ibogaine appears to rapidly reverse this deficit in preclinical models. This is mechanistically similar to ketamine's rapid antidepressant action via BDNF/TrkB signalling.

Sigma-2 Receptor Agonism

Ibogaine acts as a sigma-2 receptor agonist. Sigma receptors are increasingly recognised as modulators of neuroplasticity, cellular stress responses, and mood — and sigma-2 in particular has been linked to the pathophysiology of depression.

Serotonin and Dopamine System Reset

Ibogaine inhibits the reuptake of serotonin and dopamine and acts as a weak NMDA receptor antagonist — a mechanism it shares with the rapid-acting antidepressant ketamine. This "reset" of monoaminergic tone may underlie reports of rapid mood improvement lasting weeks to months after a single session.

Psychological and Introspective Dimension

The intense, prolonged psychedelic experience produced by ibogaine — characterised by autobiographical memory retrieval, vivid visionary states, and a period of profound introspection — is hypothesised to facilitate psychological processing of trauma, grief, and maladaptive cognitive patterns. This experiential dimension is thought to complement and potentially amplify the neurobiological effects, in a manner analogous to the therapeutic mechanism proposed for psilocybin-assisted psychotherapy in TRD.

Anti-Inflammatory Effects

Emerging evidence links neuroinflammation to TRD, with elevated inflammatory biomarkers (particularly IL-6, TNF-α, and CRP) found in treatment-resistant patients. Early research suggests ibogaine and its metabolite noribogaine may modulate microglial activity and reduce neuroinflammatory signalling, though this line of evidence remains preliminary.

Limitations and What We Don't Know Yet

Honesty about the current evidence gaps is essential for anyone considering or researching ibogaine for TRD:

  • No dedicated RCT exists. The absence of a placebo-controlled, randomised trial for TRD means we cannot yet draw firm conclusions about efficacy. Observational data and case reports are subject to selection bias, expectancy effects, and lack of long-term follow-up.
  • Optimal dosing is unknown. Ibogaine is typically administered as a single large dose (10–25 mg/kg of ibogaine HCl) in clinical settings, but the optimal dose, timing, and whether repeated lower doses are safer or comparably effective for depression has not been established.
  • Duration of effect is unclear. Case reports describe mood improvements lasting weeks, months, or — in some accounts — years. Whether ibogaine produces true remission, requires periodic re-dosing, or needs integration psychotherapy to maintain effects is not yet known.
  • TRD-specific patient population not studied. Most human ibogaine studies enrol substance-dependent populations. Whether the results translate to patients whose primary diagnosis is TRD — without concurrent substance use — is an open question.
  • Biomarker and mechanistic data in humans are thin. BDNF upregulation and neuroinflammation reduction data in humans are largely extrapolated from animal models; human biomarker studies are needed.
  • Interaction with antidepressants is a major unknown. Many TRD patients are on complex polypharmacy regimens (SSRIs, SNRIs, MAOIs, lithium, antipsychotics). The pharmacodynamic and pharmacokinetic interactions between these agents and ibogaine are poorly characterised and potentially dangerous.
  • Long-term neurological safety is unstudied. No longitudinal studies have examined repeated ibogaine exposure in humans; cerebellar toxicity has been observed in high-dose rodent models.

Safety Considerations

Ibogaine's risk profile is particularly relevant for TRD patients, who often carry comorbidities and complex medication histories that can amplify those risks.

⚠️ Ibogaine carries serious cardiac risks and has caused fatalities. Medical supervision required. Do not self-administer.

Cardiac Risk

Ibogaine blocks hERG potassium channels, prolonging the cardiac QT interval and creating risk of potentially fatal arrhythmias (Torsades de Pointes, ventricular fibrillation). In the Cherian et al. (2024) study — which used magnesium malate pre-treatment as a cardioprotective measure — one of 30 participants experienced a serious adverse event in the form of QTc prolongation. A baseline 12-lead ECG, electrolyte panel, and cardiac risk stratification are essential prerequisites. Patients with pre-existing cardiac conditions, long QT syndrome, or family history of sudden cardiac death face substantially elevated risk.

Drug Interactions in TRD Patients

This is a particularly high-stakes concern for the TRD population:

  • SSRIs/SNRIs: Combination with ibogaine may precipitate serotonin syndrome. Most protocols require a supervised washout period before treatment.
  • MAOIs: Absolutely contraindicated. Ibogaine itself has mild MAOI-like properties; combining with a prescribed MAOI creates a life-threatening risk.
  • Lithium: May lower seizure threshold when combined with ibogaine; generally considered contraindicated.
  • Antipsychotics: Many antipsychotics also prolong QT interval, creating additive cardiac risk.

Psychiatric Risk

The intense and prolonged nature of the ibogaine experience (12–36 hours) poses risk for psychological decompensation in vulnerable individuals. Active suicidality, psychosis history, bipolar I disorder, and borderline personality disorder are commonly listed as relative or absolute contraindications by ibogaine clinics, though these criteria vary between providers. Crucially, TRD patients may present with high baseline suicidality — careful screening is essential.

Noribogaine and Extended Half-Life

Ibogaine is rapidly metabolised to noribogaine, its active metabolite, which has a substantially longer half-life (28–49 hours vs. ~4–7 hours for ibogaine). This extended pharmacological activity must be accounted for in post-treatment monitoring protocols.

Current Treatment Landscape

Treatment-resistant depression is defined clinically as failure to respond to at least two adequate antidepressant trials of sufficient dose and duration. Current FDA-approved options for TRD include:

  • Esketamine (Spravato): Intranasal ketamine analog; FDA-approved for TRD since 2019. Rapid onset but requires twice-weekly clinic visits initially and carries its own dissociation and abuse potential risks.
  • Electroconvulsive therapy (ECT): Most effective biological treatment for TRD; limited by stigma, cognitive side effects, and access.
  • Transcranial magnetic stimulation (TMS): FDA-cleared; modest efficacy, better tolerability, but requires 30–36 sessions.
  • Augmentation strategies: Lithium, atypical antipsychotics (aripiprazole, quetiapine, olanzapine), thyroid hormone, and MAOIs as augmentation — effective for some, but complex polypharmacy with significant side effect burden.
  • Psilocybin-assisted therapy: Currently in Phase III trials (COMPASS Pathways, USONA Institute). Two Phase IIb trials have shown significant antidepressant effects; FDA Breakthrough Therapy designation granted.

Ibogaine currently sits outside this approved landscape, available only through clinical trials, licensed providers in jurisdictions where it is legal (Mexico, Canada, Netherlands, and others), or unregulated settings. Its potential differentiation from existing TRD treatments lies in its single-session administration model, the combination of neurobiological and experiential mechanisms, and its durability — if borne out by controlled trials. Given the substantial overlap in neurobiology with ketamine and psilocybin, ibogaine is increasingly considered part of the emerging "neuroplastogen" class of rapid-acting interventions for TRD.

Frequently Asked Questions

No. As of 2026, no randomised controlled trial has specifically tested ibogaine for treatment-resistant depression. The evidence base consists of observational studies, case reports, preclinical data, and secondary signals from trials focused on other conditions such as PTSD and substance dependence. The available signals are promising and scientifically plausible, but clinical proof is still being established.
All three are being investigated as rapid-acting neuroplasticity-promoting interventions, but they differ significantly. Ketamine (esketamine) acts primarily via NMDA receptor antagonism, has the most clinical evidence, and is FDA-approved for TRD. Psilocybin works primarily via 5-HT2A agonism and is in Phase III trials. Ibogaine has a broader, more complex pharmacology — acting on serotonin and dopamine reuptake, NMDA receptors, sigma receptors, and neurotrophic pathways simultaneously — and produces a far longer and more intense experience (12–36 hours vs. 4–6 for psilocybin). This makes it harder to study but potentially more powerful for certain patients. It also carries a substantially higher cardiac risk profile than either ketamine or psilocybin.
Not safely without medical supervision and a structured washout period. SSRIs and SNRIs require a tapering washout (typically 2–4 weeks) before ibogaine to reduce serotonin syndrome risk. MAOIs are absolutely contraindicated and require a much longer washout. Lithium is generally considered contraindicated due to seizure risk. Many antipsychotics used in augmentation strategies also carry QT-prolonging properties that compound ibogaine's cardiac risk. Any transition to ibogaine treatment must be managed by a physician experienced in both psychedelic medicine and psychopharmacology.
This is not yet well characterised in controlled research. Case reports and observational clinic data describe mood improvements ranging from weeks to months, and some individuals report lasting effects beyond a year. The Cherian et al. (2024) PTSD study showed sustained benefits at the one-month assessment point, but longer-term follow-up data are sparse. Whether integration psychotherapy, lifestyle changes, or periodic booster treatments are necessary to maintain effects remains an open question that ongoing trials are designed to answer.
Ibogaine is a Schedule I controlled substance in the United States and is similarly restricted in many countries. Legal access currently exists through licensed clinics in Mexico, the Netherlands, Canada (through approved researchers or specific provincial frameworks), Portugal, South Africa, and several other jurisdictions. Clinical trials in the US and Europe may offer another route for eligible participants. It is critical to choose a medically supervised facility with cardiac monitoring capabilities — not an informal or underground setting.
The ibogaine experience typically lasts 12–36 hours and passes through distinct phases: an initial visionary phase with vivid, often autobiographical hallucinations; an introspective phase characterised by intense emotional and memory processing; and a residual stimulant phase. Many users describe confronting past traumas, unresolved grief, or deeply held beliefs during the experience. Researchers hypothesise that this psychological processing dimension — combined with ibogaine's neuroplasticity-promoting effects — may be particularly relevant to its antidepressant properties, allowing patients to access and reframe core negative cognitions in a way that standard pharmacotherapy does not facilitate.
Dedicated trials for ibogaine in TRD are currently being developed and some are entering active recruitment phases. The best way to find current opportunities is to search ClinicalTrials.gov using the terms "ibogaine" and "depression," and to monitor registries in Canada (ISRCTN) and the EU Clinical Trials Register. Academic centres with active psychedelic research programmes — including those in Canada, Brazil, the United States, and the Netherlands — are the most likely sources of TRD-specific ibogaine trials. A qualified psychiatrist specialising in psychedelic medicine can also advise on trial eligibility.

Informational only. Not medical advice. Ibogaine is Schedule I in the US. Consult qualified professionals before considering treatment.